Iovance Biotherapeutics
New York
About Iovance Biotherapeutics
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). The company is preparing for potential regulatory approval and marketing of the first autologous T-cell treatment for solid tumor cancer in the United States. Its goal is to be the leader in tumor-infiltrating lymphocyte, or TIL, therapy innovation, development, and delivery for patients with solid tumor malignancies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $1.6B
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: nasdaq:IOVA
- Website: iovance.com
- Phone: (212)946-4856
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/iovance-biotherapeutics-44093 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.